Patient characteristics and utilization patterns of romosozumab in routine clinical practice: a European, multi-country, non-interventional study (PRIME)

First published: 15/10/2024

Last updated: 12/05/2025

Study Ongoing

Administrative details

EU PAS number

EUPAS1000000343

Study ID

1000000343

DARWIN EU® study

No

Study countries

- ☐ Belgium
- ☐ Germany
- ☐ Greece

- [ ] Italy
- [ ] Spain
- [ ] Sweden
- [ ] Switzerland
- [ ] United Kingdom

Study status

Ongoing

Contact details

Study institution contact

UCB Cares UCBCares.global@ucb.com

Study contact

UCBCares.global@ucb.com

Primary lead investigator

Alireza Moayyeri

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 29/07/2024

Study start date

Planned: 25/03/2025

Actual: 02/04/2025

Date of final study report

Planned: 04/01/2027

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

UCB Biopharma SRL

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Other

If ‘other’, further details on the scope of the study

Patient characteristics

Study drug and medical condition

Name of medicine

EVENITY

Study drug International non-proprietary name (INN) or common name

ROMOSOZUMAB

Anatomical Therapeutic Chemical (ATC) code

(M05BX06) romosozumab

romosozumab

Data management

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes